21st Annual Biotech in Europe Forum 2021 | Sachs Associates Ltd | 7 October 2021 | Virtual Event

Due to the pandemic we have decided that for the second time Sachs Basel events will be held in a digital format, thus allowing us to support our community and past attendees. We will provide both the usual stimulating programme and the networking opportunities through the online meeting system. We are constantly reviewing the situation and circumstances permitting, plan to announce in June that part of the Sachs Autumn Life Sciences Week programme will be delivered physically in Basel on the 7th and 8th of October. This would include live speeches and presentations as part of the 21st BEF with in person meetings and the event reception for both events. We will update all those who registered and when registering please indicate by ticking the appropriate box whether you would be interested in attending in person. Updates on any possible hybrid format will be posted on this website.
​
Back for its 21st Annual Edition, this global bio-pharma industry event will address through its programme the main challenges for 2021 in investment, partnering and alliance management and prospects for 2022. Key players contribute their insights in panels which cover the macro picture as well as innovation in different therapeutic sectors. This highly transactional event draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe’s pharmaceutical and biotech industry, this event will once again be covered by our regular media partners.

2021 Speakers

KEYNOTE SPEAKERS:

Nigel Sheail, Global Head of M&A and BD&L, Novartis International AG

Stephan Emmerth, Director Business Development & Operations, BaseLaunch

CHAIRS:

Agnieszka Blum, General Director of the Immunology, Ardigen S.A.

Alison Haggerty, Partner, Latham & Watkins LLP

Allan Marchington, Managing Director & Head of Life Sciences of Intermediate Capital Group Plc

Aram Mangasarian, CEO, NOXXON Pharma NV

Avaleigh Milne , Oncology Basel Site Head, Pharma Partnering, F. Hoffmann-La Roche Ltd.

Bharat Ramachandran, Director, Head of Business Development, Immunology & Global Health, EMD Serono, Inc., an affiliate of Merck in the U.S. & Canada

Bibhash Mukhopadhyay, Independent

Corinne Venot, Executive Director, Business Development, BeiGene Ltd.

Daniel Teper, CEO, Cytovia Therapeutics Inc.

Daniela Begolo, Senior Associate, INKEF Capital BV

Deborah Rathjen, Executive Chair & CEO, Bioasis Technologies, Inc.

Edyta Jaworska, Management Board Member, Selvita S.A.

Eric Halioua, President & CEO, PDC*line Pharma SA

Erik Manting, CEO, Immunicum AB

Esteban Pombo-Villar, CTO, TargImmune Therapeutics AG

Fintan Walton, Founder & CEO, PharmaVentures Ltd.

Frauke Hein, Co-Founder & CBO, Adrenomed AG

Gabriel Cavazos, Managing Director in Investment Banking , SVB Leerink

Gil Bar-Nahum, Managing Director, EMEA Head of Biotechnology, Je­eries International Ltd.

​Guillaume Vignon, SVP, Business Development, BeiGene Ltd.

Hans Herklots, Managing Director, LifeSci Advisors

​Hubert Birner, Managing Partner, TVM Life Science Management GmbH

Isabel Ferreira, Chief Business Officer, Versameb AG

Jean-Marc Bourez, EIT Health Services & Investment Co-Managing Director & French Hub Managing Director, EIT Health e.V.

Jesús Martin-Garcia, CEO, GeNeuro SA

Jie Liu, Managing Director, Torreya Partners LLP

John Alam, President & CEO, EIP Pharma, Inc.

Justyna Czyszek, Investor Support Department Vice-President, Krakowski Park Technologiczny sp. z o.o.

Kazimierz Murzyn, CEO, Klaster LifeScience Krakow

Khatereh Ahmadi, Executive Director, Oncology Search & Evaluation Lead for Europe, MSD

​Kristen Albright, CEO, Prokarium Ltd.

Lubor Gaal, Managing Director, Locust Walk

Lynn Durham, Founder & CEO, STALICLA SA

Mai-Britt Zocca, Founder & CEO, IO Biotech ApS

Marianne Uteng, Principal, Novartis Venture Fund

Marietta Wu, Managing Director, Quan Capital

Markus Hosang, General Partner, BioMedPartners AG

Martin Welschof, CEO, BioInvent International AB

Matthias Müllenbeck, SVP, Head Global BD & Alliance Management, Merck

Montserrat Cano, CEO, Nanoligent SL

Michael Altorfer, CEO, Swiss Biotech Association

Michael Huebner, Director Early Innovation Partnering, Johnson & Johnson Innovation LLC

Michael Maguire, CEO, Avectas Ltd.

Michael Rice, VP, Head of Advanced Therapeutics, Cello Health BioConsulting

Miguel Forte, CEO, Bone Therapeutics SA

Mike Romanos, Co-Founder & CEO, Microbiotica Ltd.

Mirjam Heeb, Investment Advisor, HBM Partners AG

Murali Gopalakrishnan, Global Head, Neuroscience Search & Evaluation, AbbVie, Inc.

Mythili Koneru, Chief Medical Officer, Marker Therapeutics, Inc.

Natalie Mount, CEO, Adaptate Biotherapeutics Ltd.

Nathalie ter Wengel, European Lead, Worldwide Business Development, Pfizer, Inc.

Nicholas Franco, EVP & Chief Business Development Officer, Allschwil Site Head, Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson

Olivier Reinhard, Head Of Business Development, Emerging Markets EPD of Abbott

Paul Hermant, Partner, Bird & Bird LLP

Paul Rennert, President & CSO, Aleta Biotherapeutics

Phil L'Huillier, CEO, CatalYm GmbH

Rainer Strohmenger, Managing Partner, Wellington Partners

Rao Movva, Novartis Distinguished Scientist & Independent Pharma & Biotech Advisor

Reagan Jarvis, CEO, Anocca AB

Richard Ward, Senior Director, Search & Evaluation, AstraZeneca

Sam Fazeli, Head of Research, Senior Pharmaceuticals Analyst, Bloomberg Intelligence

Sandra Ferri, Head of Life Sciences Investments, European Investment Fund

Sarah Holland, CBO, VectivBio AG

Sascha Bucher, Co-Founding Partner, Forty51 Ventures

Simone Botti, Junior Partner, INKEF Capital BV

Søren Bregenholt, CEO, Alligator Bioscience AB

​Søren Møller, Managing Partner, Novo Holdings A/S

Stefan Luzi, Partner, Gilde Healthcare Partners B.V

Stéphane Boissel, President & CEO, SparingVision

Stephanie Léouzon, Partner & Head of Europe, Torreya Partners LLP

Susan Hill, CEO, Mestag Therapeutics Limited

Susanne Wilke, President & CEO, Cognoptix, Inc.

Theodora Harold, CEO, Crescendo Biologics Ltd.

Thibaut Roulon, Senior Investment Director, Bpifrance

Thijs Cohen Tervaert, Junior Partner, INKEF Capital BV

Tim Haines, Chairman & Managing Partner of Abingworth LLP

Tim Luker, VP Venture Science, Corp BD, Eli Lilly and Company

Ulrich Wendt, Head of Immunology Business Development, Sanofi

Vanela Bushi, Director, Strategy & Transactions Europe Lead, Syneos Health, LLC

Xin Liu, Partner, Eight Roads Ventures

Yochi Slonim, Co-Founder & CEO, Anima Biotech, Inc.

2021 Sponsors

Silver Sponsors:
• Beigene Ltd.
• Eit Health E.v.
• Lifesci Advisors
• Torreya Partners Llp

Bronze Sponsors:
• Merck
• Svb Leerink

Contributing Sponsors:
• Inkef Capital Bv
• Latham & Watkins Llp
• Novo Holdings a/s
• Pharmaventures Ltd.
• Six Swiss Exchange Ag
• Syneos Health, Llc